CTGCT

Today on #RareDiseaseDay, we want to share our latest blog post highlighting the remarkable progress in treating #CTNNB1Syndrome - a rare genetic disorder that affects brain and muscle development in children. In just a few years, patient advocacy organizations like CTNNB1 Foundation, CTNNB1 Connect and Cure, Asociación Ctnnb1, CTNNB1 France and CTNNB1 Italia have raised over $3 million and built powerful collaborative networks between researchers, clinicians, and biotech companies. This extraordinary partnership is transforming what was once considered an untreatable condition into one with multiple promising therapeutic approaches, including gene therapy clinical trials expected to begin this year. Our article "How Patient Advocacy is Driving Breakthroughs to Treat #CTNNB1 Syndrome" explores: • The critical role of patient-led organizations in accelerating research • Scientific advances in understanding the disorder's mechanisms • Four innovative treatment approaches currently in development • The future of personalized medicine for rare genetic conditions At the #CTGCT, we're proud to support this important work and contribute to the bridge between scientific discovery and life-changing treatments. I invite you to read the full blog post, based on the paper published earlier this month, to learn more about this inspiring journey and how collaborative efforts between families and scientists are revolutionizing rare disease treatment. https://lnkd.in/gZKaYK4H #RareDiseaseDay #CTNNB1Syndrome #PatientAdvocacy #GeneTherapy #RareDisease #MedicalResearch

Check our latest blog post, "CONTROLLING CELLS WITH A CHEMICALY SWITCHABLE ANTIBODIES: A NEW OPPORTUNITY FOR PRECISION THERAPY" In this post, we break down the latest paper our scientist published in Cell Chemical Biology with where researchers engineered Fv-CID switches (split antibody fragments that reassemble in the presence of a safe molecule like fluorescein) to precisely control cell behavior. This innovative approach holds significant promise for improving the safety and efficacy of therapies like CAR T cells and BiTEs. Check out the blog post to learn how this technology could transform cell-based treatments. https://lnkd.in/dFgNZtMq #Biotech #CellTherapy #SyntheticBiology #Innovation #CancerResearch #CART

🧪Join us in shaping the future of medicine! the #CTGCT is hiring passionate scientists, clinicians, and innovators to drive groundbreaking discoveries. Be part of a team transforming lives through cutting-edge research. Apply today! 🥼 #recruitment #hiring #GeneTherapy #Biotechnology https://lnkd.in/d5hz4bab https://lnkd.in/dHZpn5wp

If you are a researcher at the Kemijski inštitut - National Institute of Chemistry don't hesitate to contact us for the link to this talk #translationalscience #processdevelopment #CGT

Webinar | 3 March: Bridging the Gap – Taking Viral Vectors from Bench to Clinic Join Ganesh Ramesh from Viral Vector Production Center for Translational Immunology, UMC Utrecht, as he explores this topic. He is proficient in the field of bioprocess engineering and equally passionate about molecular science. His work is on establishing a large-scale viral vector production facility in the UMC Utrecht to advance ATMP development and manufacturing. Date: 3 March 2025  Time: 1pm UK Time / 2pm CET (30 min) Open to: UCL staff and students View the webinar poster for details, UCL-login required: bit.ly/4jUP5oF This is part of the monthly webinar series organised by the Centre for the Technologies of Gene and Cell Therapy (CTGCT), a €30m EU-funded landmark initiative in Slovenia. UCL plays a key role as its strategic partner, supporting the transfer of knowledge for the translation of Advanced Therapy Medicinal Products (ATMPs) into clinical and commercial settings while engaging with the broader EU ecosystem.   #CellandGeneTherapy #TranslationalResearch #AdvancedTherapies

The 28th of February is approaching, the Day of Rare Diseases. Hugs are being collected in 7 countries to raise awareness of the importance of everyone working together to defeat rare diseases. Our colleague Gregor started here at the #CTGCT, who are you going to hug? #ObjemiZaRedke #HugForRare

On this International Day of Women and Girls in Science, we spotlight the incredible women shaping the future of gene and cell therapy at #CTGCT. From pioneering research to mentorship and leadership, their contributions are driving innovation and breaking barriers in Slovenia and beyond. 🔬 Hear their stories, challenges, and aspirations in our latest blog post. 👇 https://lnkd.in/djqqKKgG #WomenInScience #CTGCT #GeneTherapy #CellTherapy #Innovation #STEM

Webinar on 3 Feb: IP and Commercialisation - Important Things to Consider as a Researcher If you're a UCL researcher, join us for this webinar to learn more about the translation aspect of cell and gene therapy, exploring key considerations for researchers regarding IP and commercialisation. While primarily focused on cell and gene therapy, the content and principles are applicable to all modalities.   Date: 3 Feb 2025  Time: 1pm UK Time / 2pm CET (30 min) Speakers: - Dr Pamela Tranter, Head of Translational Research Group at the UCL Translational Research Office (TRO) ;  - Dr Mark Fisher, Associate Director BioPharm, UCL Business Ltd Open to: UCL staff and students Check out the webinar poster for details (UCL login required): bit.ly/3PTNQrO The webinar is organised by the Centre for the Technologies of Gene and Cell Therapy (CTGCT), a €30m EU-funded landmark initiative in Slovenia. UCL plays a key role as its strategic partner, supporting the transfer of knowledge for the translation of Advanced Therapy Medicinal Products (ATMPs) into clinical and commercial settings while engaging with the broader EU ecosystem.   #CellandGeneTherapy #TranslationalResearch #AdvancedTherapies #IP #Commercialisation

Iva Hafner Bratovič and Sara Orehek have been chosen as Names of the Week by Val 202. Check our latest article where we go over all their media appearance and how this innovative research against #cancer is gaining traction in the Slovenian media https://lnkd.in/dYZHug3h #research #innovation #CTGCT #immunotherapy #pyroptosis #cytokines #naturecomunications

Did you see our colleagues Sara Orehek and Dr.Iva Hafner Bratkovič on the national TV last Friday? Their research about combining cytokines and pyroptosis as a promising weapon against cancer is making headlines around Slovenia and on Friday they were interviewed in the program Odmevi of RTV Slovenia, a program that offers the day's most significant event news in a fresh formal with a more in-depth analysis. You can watch it here: https://lnkd.in/dgzq_wcz Or you can read the article we wrote breaking down their research. https://lnkd.in/d5YKPvvB #research #cancer #CTGCT #nationalnews #slovenia